AstraZeneca stock dives 9% after heart drug trial misses target

Shares of AstraZeneca fell as much as 9% after a late stage clinical trial for an experimental heart disease failed to meet its target.

The medicine, Wainua, did not reach its main goal of reducing deaths and recurrent heart-related emergencies over 140 weeks compared to a placebo, the British drugmaker said in a press release early Thursday.

The treatment is for a rare, life-threatening heart condition called transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

The stock was last seen down 8.9% in London, on track for its worst day since March 2020 at the start of the Covid-19 outbreak.

This is breaking news. Please refresh for updates.